DK1385551T3 - Antieoplastiske kombinationer indeholdende CCI-779 (rapamycinderivat) sammen med gemcitabin eller fluoruracil - Google Patents
Antieoplastiske kombinationer indeholdende CCI-779 (rapamycinderivat) sammen med gemcitabin eller fluoruracilInfo
- Publication number
- DK1385551T3 DK1385551T3 DK02726710T DK02726710T DK1385551T3 DK 1385551 T3 DK1385551 T3 DK 1385551T3 DK 02726710 T DK02726710 T DK 02726710T DK 02726710 T DK02726710 T DK 02726710T DK 1385551 T3 DK1385551 T3 DK 1385551T3
- Authority
- DK
- Denmark
- Prior art keywords
- gemcitabine
- neoplastic
- fluorouracil
- combinations containing
- rapamycin derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28238501P | 2001-04-06 | 2001-04-06 | |
PCT/US2002/010912 WO2002080975A1 (en) | 2001-04-06 | 2002-04-05 | Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1385551T3 true DK1385551T3 (da) | 2008-12-08 |
Family
ID=36501707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02726710T DK1385551T3 (da) | 2001-04-06 | 2002-04-05 | Antieoplastiske kombinationer indeholdende CCI-779 (rapamycinderivat) sammen med gemcitabin eller fluoruracil |
Country Status (6)
Country | Link |
---|---|
US (2) | US20020183240A1 (es) |
AR (1) | AR033012A1 (es) |
DK (1) | DK1385551T3 (es) |
EC (1) | ECSP034790A (es) |
TW (1) | TWI233359B (es) |
ZA (1) | ZA200308640B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI286074B (en) * | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
TWI296196B (en) * | 2001-04-06 | 2008-05-01 | Wyeth Corp | Antineoplastic combinations |
ZA200603888B (en) * | 2001-06-01 | 2007-05-30 | Wyeth Corp | Antineoplastic combinations |
UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
US20040258662A1 (en) * | 2003-04-22 | 2004-12-23 | Wyeth | Antineoplastic agents |
RU2405566C2 (ru) | 2005-02-03 | 2010-12-10 | Дзе Дженерал Хоспитал Корпорейшн | Способ лечения рака, устойчивого к гефитинибу |
AU2016259316B2 (en) * | 2005-11-04 | 2018-09-06 | Wyeth Llc | Antineoplastic combinations with mTOR inhibitor, herceptin, and/or HKI-272 |
PE20070763A1 (es) | 2005-11-04 | 2007-08-08 | Wyeth Corp | COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272 |
PT2275103E (pt) * | 2005-11-21 | 2014-07-24 | Novartis Ag | Inibidores de mtor para o tratamento de tumores endócrinos |
RU2473343C2 (ru) * | 2006-02-02 | 2013-01-27 | Новартис Аг | Лечение туберозного склероза |
DE102006011507A1 (de) * | 2006-03-14 | 2007-09-20 | Lts Lohmann Therapie-Systeme Ag | Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine |
TW200901989A (en) * | 2007-04-10 | 2009-01-16 | Wyeth Corp | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
MX365008B (es) | 2008-06-17 | 2019-05-20 | Wyeth Llc | Combinaciones antineoplasticas que contienen hki-272 y vinorelbina. |
JP5681108B2 (ja) | 2008-08-04 | 2015-03-04 | ワイス・エルエルシー | 4−アニリノ−3−シアノキノリンとカペシタビンの抗新生物薬の組合せ |
ES2561495T3 (es) | 2009-04-06 | 2016-02-26 | Wyeth Llc | Régimen de tratamiento que utiliza neratinib contra cáncer de mama |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA737247B (en) * | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
US3993749A (en) * | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
US4885171A (en) * | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
US4401653A (en) * | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
US5100899A (en) * | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
US5078999A (en) * | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
US5080899A (en) * | 1991-02-22 | 1992-01-14 | American Home Products Corporation | Method of treating pulmonary inflammation |
US5321009A (en) * | 1991-04-03 | 1994-06-14 | American Home Products Corporation | Method of treating diabetes |
ZA924953B (en) * | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
US5286731A (en) * | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory bowel disease |
US5286730A (en) * | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
US5516781A (en) * | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
US5288711A (en) * | 1992-04-28 | 1994-02-22 | American Home Products Corporation | Method of treating hyperproliferative vascular disease |
ZA935112B (en) * | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
US5561138A (en) * | 1994-12-13 | 1996-10-01 | American Home Products Corporation | Method of treating anemia |
US5496832A (en) * | 1995-03-09 | 1996-03-05 | American Home Products Corporation | Method of treating cardiac inflammatory disease |
US6132730A (en) * | 1997-01-22 | 2000-10-17 | Board Of Regents, The University Of Texas System | Combined tissue factor and factor VIIa methods and compositions for coagulation and tumor treatment |
US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
US5985325A (en) * | 1997-06-13 | 1999-11-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
TW466112B (en) * | 1998-04-14 | 2001-12-01 | Lilly Co Eli | Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same |
US6294546B1 (en) * | 1999-08-30 | 2001-09-25 | The Broad Of Trustees Of The Leland Stanford Junior University | Uses of diterpenoid triepoxides as an anti-proliferative agent |
US6277983B1 (en) * | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
TWI296196B (en) * | 2001-04-06 | 2008-05-01 | Wyeth Corp | Antineoplastic combinations |
ZA200603888B (en) * | 2001-06-01 | 2007-05-30 | Wyeth Corp | Antineoplastic combinations |
UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
US20040258662A1 (en) * | 2003-04-22 | 2004-12-23 | Wyeth | Antineoplastic agents |
-
2002
- 2002-03-20 TW TW091105290A patent/TWI233359B/zh active
- 2002-03-26 AR ARP020101111A patent/AR033012A1/es unknown
- 2002-04-05 DK DK02726710T patent/DK1385551T3/da active
- 2002-04-05 US US10/117,161 patent/US20020183240A1/en not_active Abandoned
-
2003
- 2003-10-05 EC EC2003004790A patent/ECSP034790A/es unknown
- 2003-11-05 ZA ZA200308640A patent/ZA200308640B/en unknown
-
2005
- 2005-04-20 US US11/110,050 patent/US20050187184A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AR033012A1 (es) | 2003-12-03 |
ZA200308640B (en) | 2008-04-30 |
US20050187184A1 (en) | 2005-08-25 |
TWI233359B (en) | 2005-06-01 |
US20020183240A1 (en) | 2002-12-05 |
ECSP034790A (es) | 2003-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1385551T3 (da) | Antieoplastiske kombinationer indeholdende CCI-779 (rapamycinderivat) sammen med gemcitabin eller fluoruracil | |
PT1289985E (pt) | Derivados de beta-carbolina uteis como inibidores da fosfodiesterase | |
HK1060062A1 (en) | Antineoplastic combinations comprising cci-779 ( rapamycin derivative) together with gemcitabine or fluorouracil | |
BRPI0508263B8 (pt) | derivados de 1, 2, 3, 4-tetra-hidro-isoquinolina, composição farmacêutica, e, uso de derivado de 1, 2, 3, 4-tetra-hidro-isoquinolina | |
PT1562902E (pt) | Derivados de 2-piridona como inibidores da elastase de neutrofilos | |
NO2014008I2 (no) | Linagliptin | |
DK1565481T3 (da) | Antivirale nukleosidderivater | |
NO20035485L (no) | Tiofenderivater som antivirale midler for flavivirusinfeksjon | |
DE602005015835D1 (de) | An der 4"- bzw. 4'-stellung substituiertes avermectin und avermectin-monosaccharid | |
DE602005002992D1 (de) | Kippmechanismus und Spiegelsystem | |
IS8575A (is) | 3-ß-D-ríbófúranósýlþíasóló [4,5-d]pýridímínnúkleósíð og notkun þeirra | |
DK1497294T3 (da) | 1,2,3,4,7,8-Hexahydro-6H[1,4]diazepino[6,7,1-ij]guinolinderivater som antipsykotiske midler og midler med adiposistas | |
IS8050A (is) | Æðaígræði | |
NO20040775L (no) | Oftalmisk sammensetning som innbefatter et askomycin | |
MA28720B1 (fr) | Derives de tetrahydroisoquinolilsulfonamides, leur preparation et leur utilisation en therapeutique | |
FR2891825B1 (fr) | Derives de la 1-amino-isoquinoline, leur preparation et leur application en therapeutique | |
NO20044092L (no) | Oftalmisk sammensetning som innbefatter ascomycin | |
BR0208566B1 (pt) | Derivados de Beta-Carbolina, Seu Uso, e composição Farmacêutica | |
DK1663982T3 (da) | Aminoquinolinderivater og deres anvendelse som adenosin-A3-ligander | |
SE0302129L (sv) | Farmaceutiska kompositioner med antibiotisk aktivitet | |
EP1545588A4 (en) | METHODS AND COMPOSITIONS FOR ACTIVATION OR INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR D AND VASCULAR ENDOTHELIAL GROWTH FACTOR C | |
MA28847B1 (fr) | Derives de pyrrole, leur preparation et leur utilisation en therapeutique | |
ATE369347T1 (de) | Trimere makrocyclisch substituierte halogen- benzolderivate | |
NO20055180D0 (no) | Sammensetninger som innbefatter makrolid T-celle immunomodulerende eller -immunosupressive stoffer i kombinasjon med antibakterielle stoffer | |
DK1603919T3 (da) | 7-Iminoderivater af camptothecin med antitumoraktivitet |